glp 1 drugs and breast cancer Study shows tiny difference in women on GLP‑1 Glucagon-like peptide-1 medicines and cancer
Description
3,4 Another agent gaining in popularity is tirzepatide (Mounjaro, Zepbound), a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA
People typically begin to see weight loss results within the first 412 weeks of treatment, including a reduction in appetite, fewer cravings, and less food noise
As appetite is often reduced on GLP-1s, getting enough protein can be challenging
To agree on the blood glucose control goals
